Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications

Journal of Steroid Biochemistry and Molecular Biology

Volumn 66, Issue 1-2, 1998, Pages 1-10

  Brodie, Angela M H ^a   Njar, Vincent C O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYLESTR 4 ENE 3,17 DIONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; CORTICOSTEROID; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; MLD 18962; TAMOXIFEN; TESTOLACTONE; UNCLASSIFIED DRUG; VOROZOLE;

ADVANCED CANCER; ATAXIA; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DROWSINESS; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; RASH; REVIEW; SIDE EFFECT; VERTIGO; WEIGHT GAIN;

ATAXIA;

EID: 0032127417     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00022-3     Document Type: Article

References (84)

1. 1. Lynn A. G. and Ries M. S., Top 5 cancers for females and males in the U.S. J. Nat. Cancer Instit. 87 (1995) 867.
2. 2. Moller Jensen O., Esteve J., Moller H. and Renard H., Cancer in the European community and its member states. Eur. J. Cancer 26 (1990) 1167-1256.
3. 3. Boring C. C., Squires T. S. and Tong T., Cancer statistics, 1993. CA Cancer J. Clin. 43 (1993) 7-26.
4. 4. Sondik E. J., Breast cancer trends: incidence, mortality and survival. Cancer 74 (1994) 995-999.
5. 5. Miller B. A., Feuer E. J. and Hankey B. F., The increasing incidence of breast cancer since 1982: relevance of early detection. Cancer Causes Control 2 (1991) 67-74.
6. 6. Levi F., Cancer incidence in five continents, Vol. VI. Eur. J. Cancer 29A (1993) 2315-2319.
7. 7. Corry J. F. and Lonning P. E., Systemic therapy in breast cancer: efficacy and cost utility. Pharmacol. Econom. 5 (1994) 198-212.
8. 8. McGuire, W. L., An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In Hormones and Cancer, Vol. 15, ed. S. Iacobelli et al. Raven Press, New York, 1980, pp. 337-344.
9. 9. Early Breast Cancer Trialists' Collaborative GroupSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. The Lancet 339 (1992) 1-15.
10. 10. Brodie A. M. H., Schwarzel W. C., Shaikh A. A. and Brodie H. J., The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen dependent processes in reproduction and breast cancer. Endocrinology 100 (1977) 1684-1694.
11. 11. Coombes R. C., Goss P., Dowsett M., Gazet J. C. and Brodie A. M. H., 4-Hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer. The Lancet 2 (1984) 1237-1239.
12. 12. Goss P. E., Coombes R. L., Powles T. J. and Brodie A. M. H., Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione - Phase 2 report. Cancer Res. 46 (1986) 4823-4826.
13. 13. Roselli C. E., Horton L. E. and Resko J. A., Distribution and regulation of aromatase activity in the rat hypothalamus and limbic systems. Endocrinology 117 (1985) 2471-2477.
14. 14. Longcope C., Pratt J. H., Schneider S. H. and Fineberg A. E., Aromatization of androgens by muscle and adipose tissue in vivo. J. Clin. Endocrinol. Metab. 46 (1978) 146-152.
15. 15. Brodie A. M. H. and Inkster S. E., Aromatase in the human testis. J. Steroid Biochem. Mol. Biol. 44 (1993) 4-6.
16. 16. Payne A. H., Perkins L. M., Georgiou M. and Quinn P. G., Intratesticular site of aromatase activity and possible function of testicular etsradiol. Steroids 50 (1987) 435-448.
17. 17. Baird D. T., Horton R., Longcope C. and Tait J. F., Steroid dynamics under steady-state conditions. Recent Prog. Horm. Res. 25 (1969) 611-634.
18. 18. Inkster S. E. and Brodie A. M. H., Immunocytochemical studies of aromatase in early and full term human placental tissues: comparison with biochemical assays. Biolog. Reprod. 41 (1989) 889-898.
19. 19. Naftolin F., Ryan K. J., Davis I. J., Reddy V. V., Flores F., Petro Z. and Kuhn M., The formation of estrogen by central neuroendocrine tissues. Recent Prog. Horm. Res. 31 (1975) 295-319.
20. 20. Inkster S. E. and Brodie A. M. H., Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: An immunocytochemical study. J. Clin. Endocrinol. Metab. 73 (1991) 717-726.
21. 21. Hemsell D. L., Grodin J., Breuner P. F., Siiteri P. K. and Macdonald P. C., Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J. Clin. Endocrinol. Metab. 38 (1974) 376.
22. 22. Thorsen T., Tangen M. and Stoa K. F., Concentrations of endogeneous estradiol as related to estradiol receptor sites in breast tumor cytosol. Eur. J. Cancer Clin. Oncol. 18 (1982) 333-337.
23. 23. van Landeghem A. A. J., Portman J. and Nabauurs M., Endogeneous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45 (1985) 2900-2906.
24. 24. Perel E., Blackstein M. E. and Killinger D. W., Aromatase in human breast carcinoma. Cancer Res. 42 (Suppl.) (1982) 3369s-3372s.
25. 25. James V. H. T., McNeill J. M., Lai L. C., Newton C. J. M., Ghilchik M. W. and Reed M. J., Aromatase activity in normal breast and breast tumor tissue: In vivo and in vitro studies. Steroids 50 (1987) 269-279.
26. 26. Killinger D. W., Perel E., Daniilescu D., Kharlip L. and Blackstein M. E., Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation. Steroids 50 (1987) 523-535.
27. 27. Miller W. R., Hawkins R. A. and Forrest A. P. M., Significance of aromatase activity in human breast cancer. Cancer Res. 42 (Suppl.) (1982) 3365s-3368s.
28. 28. Peice T., Aitken J., Head J., Mehendroo M., Meams G. and Simpson E., Determination of aromatase cytochrome P-450 messenger ribonucleic acid in human breast tissue by competitive polymerase chain reaction amplification. J. Clin. Endocrinol. Metab. 174 (1992) 1247-1252.
29. 29. Koos R. D., Banks P. K., Inkster S. E., Yue W. and Brodie A. M. H., Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction. J. Steroid Biochem. Mol. Biol. 45 (1993) 217-225.
30. 30. Lu Q., Nakmura J., Savinov A., Yue W., Weisz J., Dabbs D. J., Wolz G. and Brodie A., Expression of aromatase protein and mRNA in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancer. Endocrinology 137 (1996) 3061-3068.
31. 31. Bezwoda W. R., Mansoor N. and Dansey R., Correlation of breast tumor aromatase activity and response to aromatase inhibitor with aminoglutethimide. Oncology 44 (1987) 345-349.
32. 32. Miller W. R., Anderson T. J. and Jack W. L. J., Relationship between tumor aromatase activity, tumor characteristics and response to therapy. J. Steroid Biochem. Mol. Biol. 44 (1990) 1055-1059.
33. 33. Bradlow H. L., A reassessment of the role of breast tumor aromatization. Cancer Res. 42 (Suppl.) (1982) 3382s-3386s.
34. 34. Chen S., Besman M. J., Sparkes R. S., Zollman S., Klisak I., Mohands T., Hall P. F. and Shiveley J. F., Human aromatase: cDNA Cloning, southern blot analysis, and assignment of the gene to chromosome 15. DNA Mol. Biol. 7 (1988) 27-38.
35. 35. Simpson E. R., Mehendroo M. S., Means G. D., Kilgore M. N., Corbin C. J. and Mendelson C. R., Tissue-specific promoters regulate cytochrome P-450 expression. J. Steroid Biochem. Mol. Biol. 44 (1993) 321-330.
36. 36. Hseuh A. J. W., Adashi E. Y., Jones P. B. C. and Welsh T. H. Jr., Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr. Rev. 5 (1984) 76-127.
37. 37. Simpson E. R., Ackerman G. E., Smith M. E. and Mendelson C. R., Estrogen formation in stromal cells of adipose tissue of women: induction of glucocorticosteroids. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 5690-5694.
38. 38. Mendelson C. R., Cleland W. H., Smith M. E. and Simpson E. R., Regulation of aromatase activity of stromal cells derived from human adipose tissue. Endocrinology 111 (1982) 1077-1085.
39. 39. Cole P. A. and Robinson C. H., Mechanism and inhibition of cytochrome P-450 aromatase. J. Med. Chem. 33 (1990) 2933-2944.
40. 40. Akhtar M., Njar V. C. O. and Wright J. N., Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J. Steroid Biochem. Mol. Biol. 44 (1993) 375-387.
41. 41. Corbin C. J., Graham-Lorence S., McPhaul M., Mason J. I., Mendelson C. R. and Simpson E. R., Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in non-steroidogenic cells. Proc. Acad. Sci. U.S.A. 85 (1988) 8948-8953.
42. 42. Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F. J., Guengerich F. P., Gunsalas I. C., Johnson E. F., Loper J. C., Sato R., Waterman M. R. and Waxman D. J., The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Mol. Biol. 10 (1991) 1-14.
43. 43. Schwarzel W. C., Kruggel W. and Brodie H. J., Studies on the mechanism of estrogen biosynthesis. VII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92 (1973) 866-880.
44. 44. Santen R.., Santner S. and Lipton A., Aromatase: new pespectives for breast cancer. Cancer Res. 42 (Suppl.) (1982) 3267s-3468s.
45. 45. Santen R. J., Aromatase: future pespectives. Steroids 50 (1987) 1-665.
46. 46. Brodie A., Brodie H. R., Callard G., Robinson C. H., Roselli C. and Santen R., Recent advances in steroid biochemistry and molecular biology. Proceedings of the third international aromatase conference-basic and clinical aspects of aromatase. J. Steroid Biochem. Mol. Biol. 44 (1993) 321-693.
47. 47. Covey, D. F., Aromatase inhibitors: specific inhibition of oestrogen biosynthesis. In Steroid Biosynthesis Inhibitors, ed. D. Berg and M. Plempel, Chap. 22, 1988, pp. 534-571.
48. 48. Brueggemeier R. W., Biochemical and molecular aspects of aromatase. J. Enzym. Inhib. 4 (1990) 101-111.
49. 49. Brodie A. M. H. and Njar V. C. O., Aromatase inhibitors and breast cancer. Semin. Oncol. 23 (Suppl.) (1996) 10-20.
50. 50. Sjoerdsma A., Suicide inhibitors as potential drugs. Clin. Pharmacol Ther. 30 (1981) 3-22.
51. 51. Segaloff A., Weeth J. B., Rongone E. L., Murison P. J. and Bowers C. Y., Hormonal therapy in cancer of the breast. Cancer 13 (1960) 1017-1020.
52. 1-testolactone. J. Clin. Endocrinol. Metab. 49 (1979) 672-676.
53. 53. Covey D. F. and Hood W. F., A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase. Cancer Res. 42 (Suppl.) (1982) 3327s-3333s.
54. 1-testolactone in advanced breast cancer. Cancer 33 (1974) 9-13.
55. 55. Cash R., Brough A. J., Cohen M. N. P. and Satoh P. S., Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trials. J. Clin. Endocrinol. Metab. 27 (1967) 1239-1248.
56. 56. Thompson E. A. and Sitteri P. K., The involvement of human placental microsomal cytochrome P-450 in aromataization. J. Biol. Chem. 249 (1974) 5373-5378.
57. 57. Samojlik E., Santen R. J. and Wells S. A., Adrenal suppression with aminoglutethimide II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J. Clin. Endocrinol. Metab. 45 (1977) 480-487.
58. 58. Manni, A. and Santen, R. J., In Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, ed. B. J. A. Furr and A. E. Wakeling. Bailliere Tindall, London, 1987, pp. 271.
59. 59. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E. and Ruby E., Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab. 47 (1978) 1257-1265.
60. 60. Lrnning P. C. and Johannessen D. C., Treatment of breast cancer with aromatase inhibitors. Drugs Today 27 (1991) 117-132.
61. 61. Harris A. L., Powles T. J. and Smith I. E., Aminiglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res. 42 (Suppl.) (1982) 3405s-3408s.
62. 62. Dowsett, M. and Coombes, R. C., The development of the new aromatase inhibitor 4-OHA. Endocrine and clinical aspects. Proceedings of the Symp. Aromatase Inhibition -Past, Present and Future. 15th Int. Cancer Congr., Hamburg, 1990, pp. 9-10.
63. 63. Possinger K., Jonat W. and Hoffken K., Formestane in the treatment of advanced postmenopausal breast cancer. Ann. Oncol. 5 (1994) S7-S10.
64. 64. Bajetta, E., Zilemba, N., Norersco, C. and Bichisoa, E., Formestane: Effective therapy in postmenopausal women with advanced breast cancer. In Selective Aromatase Inhibitors -Improved Quality of Life for Metastatic Breast Cancer Patients, ed. G. Nagel, K. Possinger, Excerpta Oncol. Ciba. Ciba-Geigy Verlag, Wehr/Barden, 1996, pp. 51-56.
65. 65. Cunningham D., Powles T. J., Dowsett M., Hutchinson G., Brodie A. M. H., Ford H. T., Gazet J. C. and Coomes R. C., Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother. Pharmacol. 20 (1987) 253-255.
66. 66. Dowsett M., Goss P. E., Powles T. J., Brodie A. M. H., Jeffcoate S. L. and Coombes R. C., Use of aromatase inhibitor 4-hydroxyandrostenedione in post-menopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 147 (1987) 195-196.
67. 67. Dowsett M. and Coombes R. C., Second generation aromatase inhibitor - 4-OHA. Breast Cancer Res. Treat. 30 (1994) 81-87.
68. 68. Coombes R. C., Hughes S. W. M. and Dowsett M., 4-OHA: a new treatment for breast cancer. Eur. J. Cancer 28A (1992) 1941-1945.
69. 69. Dowsett, M., Johnston, S. R. D., Haynes, B. P., Sacks, N. P., Baum, M. B., Ebbs, S. R. and Smith, I. E., Impaired intratumoral uptake of tamoxifen as a mechanism for resistance in human breast cancer. The 84th Annu. Meet, of Am. Assoc. for Cancer Res., Orlando, FL, 1993, Abs. #1463.
70. 70. Gottardis M. M. and Jordan V. C., Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187.
71. 71. Perez Carrion R., Alberola Candel V., Calabresi F., Th. Michel R., Santos R., Delozier T., Goss P., Mauriac L., Feuihade F., Freue M., Pannuti F., Van Belle S., Martinez J., Wehrle E. and Royce C. M., Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. 5 (Suppl. 7) (1994) 519-524.
72. 72. Bhatnagar A. S., Hausler A., Trunet P., Schieweck K., Lang M. and Bowman P., Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 37 (1990) 1021-1027.
73. 73. Iverson T. J., Smith I. E., Ahern J., Smithers D. A., Trunet P. F. and Dowsett M., Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 77 (1993) 324-331.
74. 74. Smith, I. E., Letrozole: Creating a new standard. In Advanced Breast Cancer. Reassessing Hormonal Therapy-Ciba International Symposium Series, Vol. 2. The Parthenon Publishing Group, New York, 1996, pp. 45-55.
75. 75. Bisagni C., Cocconi G. and Ceri C. et al., CGS 20267: a new oral aromatase inhibitor: phase I study in postmenopausal advanced breast cancer patients. Proc. Am. Soc. Clin. Oncol. 12 (1993) 80.
76. 76. Tominaga, T., Phase II trial of letrozole in postmenopausal patients with advanced or recurrent breast cancer. In Advanced Breast Cancer. Reassessing Hormonal Therapy-Ciba International Symposium Series, Vol. 2. The Parthenon Publishing Group, New York, 1996, pp. 57-63.
77. 77. Letrozole International Trial Group (AR/BC2).
78. 78. Plourde P. V., Dyroff M. and Dukes M., Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat. 30 (1994) 103-111.
79. 79. Plourde P. V., Dyroff M., Dowsett M., Demers L., Yates R. and Webster A., Arimidex: a new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 53 (1995) 175-179.
80. 80. Yates R. A., Dowsett M., Fisher G. V., Selen A. and Wyld P. J., Arimidex (ZD 1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br. J. Cancer 73 (1996) 543-548.
81. 81. Buzdar A., Jonat W., Howell A., Jones S. E., Blomqvist C., Vogel C. L., Eiermann W., Wolter J. M., Azab M., Webster A. and Plourde P. V., Anastrozole (ARIMIDEX), a potent and selective aromatase inhibitor vs megesterol acetate (MEGACE) in postmenopausal women with advanced breast cancer: Results of an overview analysis of two phase III trials. J. Clin. Oncol 14 (1996) 2000-2011.
82. 82. Jonat W., Howell A., Blomqvist C., Eiermann W., Winalad G., Tyrrell C., Mauriac H. R., Lundgren S., Hellmund R. and Azab M., A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole ("ARIMIDEX") with megasterol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A (1996) 404-412.
83. 83. Buzdar, A., Jonat, W., Howell, A., Yin, H. and Lee, D., Significant improved survival with Arimidex (anastrozole) vs megestrol acetate (MA) in postmenopausal advanced breast cancer: Updated results of two randomized trials. ASCO Annu. Meet., Denver, CO, May 17-20, 1997.
84. 84. Crutz J. M., Muss H. B., Brockschmidt J. K. and Evans G. W., Weight changes in women with metastic breast cancer treated with megesterol acetate: a comparison of standard vs high-dose therapy. Semin. Oncol. 17 (suppl 9) (6) (1990) 63-67.